Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Concerns about the company's future growth are likely keeping investors away.

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on ...

Market Catalysts host Julie Hyman takes a closer look at some of the trending tickers during Tuesday's trading session.

Stock futures are sharply higher amid hopes that the U.S. government shutdown could end soon, while investors prepare for a ...

Pfizer's agreement to buy Metsera just adds to the 83 healthcare deals counted by Goldman Sachs that were above $100 million ...